124 related articles for article (PubMed ID: 17713326)
1. Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Gibson RJ; Bowen JM; Alvarez E; Finnie J; Keefe DM
Chemotherapy; 2007; 53(5):360-9. PubMed ID: 17713326
[TBL] [Abstract][Full Text] [Related]
2. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
Gibson RJ; Stringer AM; Bowen JM; Logan RM; Yeoh AS; Burns J; Alvarez E; Keefe DM
Cancer Biol Ther; 2007 Apr; 6(4):541-7. PubMed ID: 17457046
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
Logan RM; Gibson RJ; Bowen JM; Stringer AM; Sonis ST; Keefe DM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):33-41. PubMed ID: 17703303
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
Bateman E; Weaver E; Klein G; Wignall A; Wozniak B; Plews E; Mayo B; White I; Keefe D
Support Care Cancer; 2016 Jan; 24(1):377-385. PubMed ID: 26081596
[TBL] [Abstract][Full Text] [Related]
5. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Gibson RJ; Bowen JM; Keefe DM
Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
Stringer AM; Gibson RJ; Bowen JM; Logan RM; Ashton K; Yeoh AS; Al-Dasooqi N; Keefe DM
Int J Exp Pathol; 2009 Oct; 90(5):489-99. PubMed ID: 19765103
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Stringer AM; Gibson RJ; Logan RM; Bowen JM; Yeoh AS; Laurence J; Keefe DM
Cancer Chemother Pharmacol; 2009 Jun; 64(1):123-32. PubMed ID: 18998135
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.
Al-Dasooqi N; Gibson RJ; Bowen JM; Logan RM; Stringer AM; Keefe DM
Exp Biol Med (Maywood); 2010 Oct; 235(10):1244-56. PubMed ID: 20682600
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
[TBL] [Abstract][Full Text] [Related]
10. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
Sezer A; Usta U; Cicin I
Med Oncol; 2009; 26(3):350-7. PubMed ID: 19067257
[TBL] [Abstract][Full Text] [Related]
11. Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.
Bowen JM; Gibson RJ; Stringer AM; Chan TW; Prabowo AS; Cummins AG; Keefe DM
Anticancer Drugs; 2007 Feb; 18(2):197-210. PubMed ID: 17159606
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.
Mayo BJ; Stringer AM; Bowen JM; Bateman EH; Keefe DM
Cancer Chemother Pharmacol; 2017 Feb; 79(2):233-249. PubMed ID: 27770239
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Bowen JM; Gibson RJ; Cummins AG; Tyskin A; Keefe DM
Cancer Chemother Pharmacol; 2007 Feb; 59(3):337-48. PubMed ID: 16799812
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
Lima-Júnior RC; Freitas HC; Wong DV; Wanderley CW; Nunes LG; Leite LL; Miranda SP; Souza MH; Brito GA; Magalhães PJ; Teixeira MM; Cunha FQ; Ribeiro RA
Br J Pharmacol; 2014 May; 171(9):2335-50. PubMed ID: 24428790
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-Induced Mucositis Is Associated with Goblet Cell Dysregulation and Neural Cell Damage in a Tumour Bearing DA Rat Model.
Thorpe D; Butler R; Sultani M; Vanhoecke B; Stringer A
Pathol Oncol Res; 2020 Apr; 26(2):955-965. PubMed ID: 30919275
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Dahlgren D; Rosenqvist E; Hellström PM; Nygren P; Kullenberg F; Peters K; Sjöblom M; Lennernäs H
Basic Clin Pharmacol Toxicol; 2022 Dec; 131(6):536-546. PubMed ID: 36124882
[TBL] [Abstract][Full Text] [Related]
17. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Coller JK; Bowen JM; Ball IA; Wardill HR; van Sebille YZ; Stansborough RL; Lightwala Z; Wignall A; Shirren J; Secombe K; Gibson RJ
Cancer Chemother Pharmacol; 2017 Feb; 79(2):431-434. PubMed ID: 28011980
[TBL] [Abstract][Full Text] [Related]
18. Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis.
Fakiha K; Coller JK; Logan RM; Gibson RJ; Bowen JM
Support Care Cancer; 2019 Jun; 27(6):2313-2320. PubMed ID: 30350190
[TBL] [Abstract][Full Text] [Related]
19. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
[TBL] [Abstract][Full Text] [Related]
20. Role of regulatory T cells in irinotecan-induced intestinal mucositis.
Fernandes C; Wanderley CWS; Silva CMS; Muniz HA; Teixeira MA; Souza NRP; Cândido AGF; Falcão RB; Souza MHLP; Almeida PRC; Câmara LMC; Lima-Júnior RCP
Eur J Pharm Sci; 2018 Mar; 115():158-166. PubMed ID: 29307857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
